Environmental

Low Direct Environmental Footprint: Incyte operates primarily as a biopharmaceutical company with limited manufacturing and a focus on R&D, resulting in a relatively low direct carbon and resource footprint compared to peers with large-scale production facilities.

Sustainability Reporting and Initiatives: The company has increased transparency in its sustainability disclosures, including reporting on energy use and waste management, and has set preliminary goals for reducing environmental impact, though these targets are less ambitious than some large-cap peers.

Product Lifecycle and Supply Chain Management: Incyte has implemented responsible sourcing and waste management practices in its supply chain, but lacks comprehensive third-party environmental audits or science-based emissions targets, which are increasingly standard among industry leaders.

Incyte demonstrates a strong environmental profile for its sector, with low operational emissions and improving sustainability disclosures. However, the absence of robust, science-based targets and third-party verification leaves room for further alignment with best-in-class peers.

Social

Workforce Development and Retention: Incyte invests heavily in R&D, with nearly 40% of revenue allocated, supporting talent development and innovation. Employee turnover rates are in line with industry averages, and the company offers competitive compensation, though stock-based compensation is moderate at 3.2% of revenue.

Diversity, Equity, and Inclusion (DEI): The company has made progress in gender and ethnic diversity at the management level, but overall DEI metrics lag behind leading pharmaceutical peers, and public disclosure on pay equity and advancement remains limited.

Patient Access and Community Engagement: Incyte has expanded patient assistance programs and collaborates with advocacy groups to improve access to therapies, but faces ongoing scrutiny over drug pricing and affordability, a sector-wide challenge.

Incyte's social performance is moderate, supported by strong R&D investment and patient engagement. However, limited DEI transparency and sector-wide pricing concerns constrain its social score relative to best-in-class peers.

Governance

Board Independence and Diversity: The board is majority independent and includes members with relevant industry and scientific expertise, but gender and ethnic diversity are below the median for large-cap biotech peers.

Executive Compensation Alignment: Executive pay is closely tied to performance metrics, with stock-based compensation at a moderate level (3.2% of revenue), but some investors have raised concerns about long-term incentive structures and transparency.

Risk Management and Compliance: Incyte maintains robust compliance programs and has not faced material regulatory or legal actions in recent years. However, the company’s risk disclosures on clinical trial and supply chain risks are less detailed than some peers.

Incyte’s governance is generally sound, with strong board independence and compliance. Opportunities remain to enhance board diversity and improve transparency in executive compensation and risk disclosures.

Overall Score

Incyte demonstrates strong ESG performance relative to its biopharma peers, with a low environmental footprint, robust R&D investment, and sound governance. The company’s main areas for improvement are in DEI transparency, board diversity, and the adoption of more ambitious environmental targets. Overall, Incyte is well-positioned on ESG fundamentals, though not yet at best-in-class levels.